Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players. Antibody-drug conjugates represent a highly potent approach to treating cancer patients. They harness the precision of monoclonal antibodies, directing them towards specific antigens, to deliver potent cytotoxic drugs. This approach enhances drug effectiveness while minimizing the adverse effects typically associated with traditional chemotherapy.
Attractive Opportunities in the Antibody Drug Conjugates Market.
To know about the assumptions considered for the study, Request for Free Sample Report
Antibody Drug Conjugates Market Dynamics
Driver: Increased investment and collaborations by key market players for the development of novel ADCs
Antibody drug conjugate is a rapidly growing field. Significant investments are needed for R&D, clinical trials, and manufacturing of ADCs. Large biopharmaceutical companies are heavily investing in expansion of development and manufacturing capabilities for ADCs, deals including licensing and collaboration agreements and mergers between a big pharmaceutical company and a biotech firm specializing in antibody-based cancer therapies. According to data from Biomedtracker, between January 2018 and March 2023, there have been around 100 licensing deals for ADCs. There were only 4 ADC licensing agreements recorded in 2018, which reached 33 in 2022. 11 ADC-focused licensing deals were announced in the first three months of 2023. For instance, in April 2023, BioNTech signed a USD 170 million licensing deal with Duality Biologics (China) for exclusive access to two ADCs.
Restraint: Side effects associated with ADCs
ADCs have a reasonable side-effect profile due to high selectivity. Among the approved 11 ADCs, the most common severe side effect is hematotoxicity, which includes neutropenia, thrombocytopenia, leukopenia, and anemia. Hematotoxicity, combined with hepatotoxicity and gastrointestinal reactions, is probably induced due to the premature release of cytotoxic payloads into blood circulation. Moreover, the immune response induced by the antibody part of ADC may cause secondary injuries, resulting in nephrotoxicity. According to recent clinical observations, potential lung toxic effects like ILD have been observed during the ADC treatment period, particularly in anti-HER2 ADCs. Several death cases have been reported to be related to ILD during the clinical trials of T-DM1 and DS-8201. The detailed mechanism of action of ILD, however, remains unclear. Therefore, the corresponding optimizations of next-generations of ADC are expected to minimize side effects.
Opportunity: Adoption of combination therapies
Combination therapies utilizing antibody-drug conjugates offer significant market growth potential and are an appealing strategy for both existing and growing pharmaceutical & biotechnology businesses. ADCs have been actively studied in combination with other anticancer agents such as chemotherapy, targeted therapy, immunotherapy, and anti-angiogenic agents in recent years. The drug combinations including anti-angiogenic medicines, HER2-targeted medications, DNA damage response agents, and immune checkpoint inhibitors (ICIs) are currently in active research. More recently, strategies for combining immunotherapy with ADCs have also entered clinical studies. There is growing evidence that ADCs can improve immunotherapy efficacy by inducing immunogenic cell death, dendritic cell maturation, increased T-lymphocyte infiltration, enhanced immunological memory, and the production of immunomodulatory proteins such as PD-L1 and MHC.
Challenge: Technical complexities
ADCs comprise a tumor antigen-specific antibody, a potent cytotoxic payload and a stable chemical linker that joins the antibody to the cytotoxic drug. The individual characteristics and risks associated with these three components present unique challenges and pose considerable risks at multiple levels. Achieving an optimal balance between the potency of the cytotoxic drug and the specificity of the antibody is one of the major issues. Another challenge is the potential for toxicity, particularly in non-target tissues. The cytotoxic payload can cause damage to healthy cells, leading to adverse effects and limiting the potential use of ADCs in treating certain cancers. Further, the process of bioconjugation is complex, and there are numerous factors that can affect the stability of the final product which can impact the efficacy and safety of the ADC. The advancements in linker and payload technologies and the emergence of new manufacturing technologies helped to overcome such challenges in ADC development.
Ecosystem Analysis Antibody Drug Conjugates Market
The Kadcyla segment of the antibody drug conjugates industry held the dominant position in 2022.
On the basis of product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and Others. The Kadcyla segment dominated the antibody drug conjugate market during the forecast period. The rising prevalence of breast cancer coupled with increased approvals for the ADCs for breast cancer treatment are some of the factors driving the market growth.
Blood Cancer Segment of the antibody drug conjugates is likely to grow at significant CAGR during the forecast period.
On the basis of disease type, the global antibody drug conjugates market is segmented into breast cancer, blood cancer and others. The breast cancer segment dominated the market in 2022 owing to various factors such as increased adoption of ADCs for treatment by patient population. The increasing number of clinical trials on ADCs for breast cancer and the recent approvals of ADCs target indications, such as blood cancer, lung cancer, cervical cancer, and ovarian cancer among others is further expected to project the market growth at faster pace.
Asia Pacific region of the antibody drug conjugates industry is likely to grow at the highest CAGR during the forecast period of 2023-2028.
The antibody drug conjugates market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. A robust product pipeline and increased regulatory approvals of ADCs are likely to propel the market growth in the region. Asia Pacific segment is likely to grow at a higher CAGR owing to various factors such as the increasing number of cancer cases coupled with the rise in the use of ADCs for the treatment of cancer. Furthermore, the launch of biosimilar Ujivra by Zydus is likely to have a positive impact on the market growth in the coming years.
Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Key players in the antibody drug conjugates market include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India)
Scope of the Antibody Drug Conjugates Industry:
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$9.7 billion |
|
Estimated Value by 2028 |
$19.8 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 15.2% |
|
Market Driver |
Increased investment and collaborations by key market players for the development of novel ADCs |
|
Market Opportunity |
Adoption of combination therapies |
This report categorizes the antibody drug conjugates market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Kadcyla
- Enhertu
- Adcetris
- Padcev
- Trodelvy
- Polivy
- Others
By Disease Type
- Breast Cancer
- Blood Cancer
- Others
By Linker Type
- Non-Cleavable
- Cleavable
By Target
- HER2
- CD22
- CD30
- Others
By Payload Type
- MMAE/auristatin
- calicheamicin
- Maytansinoids
- Others
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
-
Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
Recent Developments of Antibody Drug Conjugates Industry
- In July 2023, ImmunoGen, Inc., entered into a multi-target license and option agreement with ImmunoBiochem to develop next-generation antibody-drug conjugates.
- In July 2023, BeiGene and DualityBio entered into a partnership to advance differentiated antibody drug conjugate (ADC) therapy for solid tumors.
- In June 2023, Lonza acquired Synaffix B.V. a biotechnology company involved in commercializing clinical-stage technology platforms for the development of antibody drug conjugates.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global antibody drug conjugates market?
The global antibody drug conjugates market boasts a total revenue value of $19.8 billion by 2028.
What is the estimated growth rate (CAGR) of the global antibody drug conjugates market?
The global antibody drug conjugates market has an estimated compound annual growth rate (CAGR) of 15.2% and a revenue size in the region of $9.7 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This study involved four major activities in estimating the current size of the antibody drug conjugates market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the antibody drug conjugates market. The secondary sources used for this study include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), the Global Cancer Observatory (GLOBOCAN), the National Institutes of Health (NIH), the Center for Disease Control & Prevention (CDC), US Department of Health and Human Services, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information (NCBI), World Cancer Research Fund International (WCRF International), European Medicines Agency (EMA), The National Medical Products Administration (NMPA), The Central Drugs Standard Control Organisation (CDSCO); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global antibody drug conjugates market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the antibody drug conjugates market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The major players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the antibody drug conjugates business of players operating in the market have been determined through secondary research and primary analysis.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Market Size Estimation Methodology-Bottom-up approach
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach-
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
An antibody-drug conjugate (ADC) is a specialized type of pharmaceutical compound consisting of three key components: a monoclonal antibody, a linker molecule, and a cytotoxic drug (chemotherapy agent). The monoclonal antibody component is designed to target and bind to specific antigens or proteins found on the surface of cancer cells. The linker molecule connects the antibody to the cytotoxic drug. Once the antibody attaches to the cancer cell, the ADC is internalized by the cell, and the linker releases the cytotoxic drug directly into the cancer cell, causing cell death. This targeted approach enhances the effectiveness of the chemotherapy while minimizing damage to healthy cells, reducing side effects compared to traditional chemotherapy. ADCs have emerged as a promising and precise treatment option for certain types of cancer.
Key Stakeholders
- Antibody drug conjugate manufacturers
- Antibody drug conjugates associations
- Cancer research institutes
- Antibody drug conjugates raw material suppliers
- Biotechnology & biopharmaceutical companies
- Drug manufacturers, vendors, and distributors
- Academic & government research institutes
- Venture capitalists & investors
- Government organizations
- Private research firms
- Research & development (R&D) companies
- Hospitals and Speciality Clinics
The main objectives of this study are as follows:
- To define, describe, and forecast the antibody drug conjugates market by product, disease type, linker type, target, payload type and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall antibody drug conjugates market.
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA)
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, acquisitions partnerships, agreements, and collaborations
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
- Country-wise Information:
- Analysis for additional countries (up to five)
- Company Information:
- Detailed analysis and profiling of additional market players (up to five)
Growth opportunities and latent adjacency in Antibody Drug Conjugates (ADC) Market